{"id":829627,"date":"2025-03-25T16:09:27","date_gmt":"2025-03-25T20:09:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/"},"modified":"2025-03-25T16:09:27","modified_gmt":"2025-03-25T20:09:27","slug":"molecular-partners-to-hold-three-poster-presentations-at-aacr-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/","title":{"rendered":"Molecular Partners to hold three poster presentations at AACR 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <em>Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with <\/em><br \/>\n        <sup><br \/>\n          <em>212<\/em><br \/>\n        <\/sup><br \/>\n        <em>Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer<\/em>\n      <\/p>\n<p>\n        <em>First preclinical data on second <\/em><br \/>\n        <sup><br \/>\n          <em>212<\/em><br \/>\n        <\/sup><br \/>\n        <em>Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors <\/em>\n      <\/p>\n<p>\n        <em>Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors<\/em>\n      <\/p>\n<p>ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March  25, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W0hAq51Ln1hfC0icReV3Aszk72nWK0gvYaYKY1DHPurV2SpkC7mWj7i9djtupEPSht-McHzUPmUCctRqv7GF5Uo0ljbsZclWwMOyxd6mSzY=\" rel=\"nofollow\" target=\"_blank\">Molecular Partners<\/a> AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today announced it will hold three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, IL.<\/p>\n<p>\n        <strong>Details of the presentations:<\/strong>\n      <\/p>\n<p>\n        <strong>MP0712, the first anti-DLL3 <\/strong><br \/>\n        <sup><br \/>\n          <strong>212<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>Pb Radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC)<\/strong><br \/>\n        <br \/>Session Category: Experimental and Molecular Therapeutics<br \/>Session Title: Biochemical Modulators of Cancer \/ Differentiation Therapeutic Strategies<br \/>Session Timing: Sunday April 27 at 2:00pm &#8211; 5:00pm CST<br \/>Location: Poster Section 16, Poster Board Number: 13<br \/>Published Abstract Number: 346<\/p>\n<p>\n        <strong>Development of <\/strong><br \/>\n        <sup><br \/>\n          <strong>212<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumors<\/strong><br \/>\n        <br \/>Session Category: Experimental and Molecular Therapeutics<br \/>Session Title: Biochemical Modulators of Cancer \/ Differentiation Therapeutic Strategies<br \/>Session Timing: Sunday April 27 at 2:00 \u2013 5:00pm CST<br \/>Location: Poster Section 16, Poster Board Number: 6<br \/>Published Abstract Number: 339<\/p>\n<p>\n        <strong>Next-generation multi-specific and conditionally activated CD3 Switch-DARPins with CD2 co-stimulation to tackle the current limitations of T cell engagers in solid tumors<\/strong><br \/>\n        <br \/>Session Category: Experimental and Molecular Therapeutics<br \/>Session Title: Therapeutic Approaches to Attack the Tumor Microenvironment<br \/>Session Timing: Monday April 28 at 2:00pm \u2013 5:00pm CST<br \/>Location: Poster Section 24, Poster Board Number: 3<br \/>Published Abstract Number: 3119<\/p>\n<p>\n        <strong>About Molecular Partners AG\u00a0<\/strong><br \/>\n        <br \/>Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eYdUgsrTDpDM8e2bqB8DibLkg5rtoMPdXGgRq21Ce6SQNXVwcdpirK7st7xhCLT6-qdsa9KbznEyXlvi51-D5xAKI_xhjmXY0TlWEP5ShfwLJpTuolr4L2zufTzj8NZr6fGcvbAyvATA4ObRpP8GPTRZCDcX5vcrOzf6AykcWOYaWBsndP7iDCc7jJcuuPHgPLoU9WPgVdZApx7nhKJ9UJLsey2sMxAEiwi8U34nPlzlBs-89QTpZa6DQUrezGdhfYU-H_GmJVzXI7eiHTgEaElnj2dqRrPvBIkiJzkFv_vVRj7a6RawN3Q2J5CVJXgwIZ3Km6GmpaZGpP0GO0KmPZpU8JywGYj1v-wLnmcsgdt4V2O1InivYyzT0kE-l3GCcgXMFeUFjo09TFndh0S6jfcWrpbHzql3X_l8wKFRHOoKPEhn0fKlk1IPLxpVqpCznfezFfigmNhwdmzQVIoQdARt0VwXfQ-bLVSf_CnBJ0PRufLplsyo5yo-_Pn1K1mF1ULQbelRo5pKsKxVyt6nKPxFztwHcnXtZh9Q6CTX9bp7WL85f2uGuTTOateIbp8fqeZV3FVlqJviXu0rAjToXpRwDyPf-t1dBIIaMoHkPmFCKJIKVojD2B_DbS8iPReGFu17NoYJe5edQYhXCRO7ptC2WzyotPLj0Mr0XeLSNrQGQ6WVKw_38zCHZ3En_1GmTr_fcSQ3QQXsYrPZQrnOFqUXW4uf4E9qIAToGSV-XSKsGSigQm8LGAQHqaay4yhdTF5yVt1rQ9cxNTOup3meaDGtona1--VvTRMwnqtBoWNTdM73SDW_YmMv1SE5YYbrws7j9CEdkxmhw_y1mIGqDA==\" rel=\"nofollow\" target=\"_blank\">www.molecularpartners.com<\/a>\u00a0and find us on LinkedIn and Twitter\/X \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QflX-P_9trNSTBrGOKzCK2OTPBbOljrahIt2us6tnlVF4AVuUvnatbIFmSEIgj65yOnnrcI2HGYRcp4mPnI2HQXXAS4jeRYmmcMf8bunQAnD_49-yS4A6rCBXpQY8cJW60gcBVxv9rD5zysqTzHwsasw7HeVZCXyvuepat2Oi_OzlIUq1qniIN7Fsf75Lt6L-zbv2jXWCt5CGDzBAq82VNltYfR24zLCFC9-VRluhFkDDCz9Lw-ttnghacboCJdkslnrvwEwzVQF2IEI0lldRps6QjQvxM4XUAjzoJeU-i4giWb71QdoacnjsNbr_i4laDiRg1kUZUHC5NjkLPvZG10gsYOsIHXBpgNxBsargbgp935Cg9bxKJG9ace2XTg3OF3i83MvMNkjxPd77z7RdNDN0ItvNaWciplp3-SCaXo7zDR7VdoxGWooKDivXlrgfrd62pp3PSjy8yunwZSrfoNQZHu4HNC2IOOcAPLMKzlUsjZerVNSJhNyD5aorH7dp_Ejokbj-chC5qmTI9atrfla6_rwFTO654VZO2QMouDVWSMx5bNDKFR6LrcASme2PiF57ttb5psE5x93IH-65sT27w-_MzMBjhg1UlIv_sKPhUh5b7dSvlOdUbqqtAiD6uXKfiANnUEAluh-VtdJslZAQEPr6BIPc2Qwn4EHTtr8N6zptXvyco75RkUVh0nJTRxk3-vKCx_jnxpB6ZjdY2wVidVa90ET9TpX3iGnPfs=\" rel=\"nofollow\" target=\"_blank\">@MolecularPrtnrs<\/a><\/p>\n<p>\n        <strong>For further details, please contact:<\/strong><br \/>\n        <br \/>Seth Lewis, SVP Investor Relations &amp; Strategy<br \/>Concord, Massachusetts, U.S.<br \/>seth.lewis@molecularpartners.com<br \/>Tel: +1 781 420 2361<\/p>\n<p>Laura Jeanbart, PhD, Head of Portfolio Management &amp; Communications<br \/>Zurich-Schlieren, Switzerland<br \/>laura.jeanbart@molecularpartners.com<br \/>Tel: +41 44 575 19 35<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners\u2019 current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners\u2019 product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners\u2019 collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners\u2019 expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as \u201caim\u201d, &#8220;anticipate&#8221;, \u201cexpect\u201d, \u201cguidance\u201d, \u201cintend\u201d, \u201coutlook\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cwill\u201d and similar expressions, and are based on Molecular Partners\u2019 current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners\u2019 expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners\u2019 reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners\u2019 ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners\u2019 ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners\u2019 product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners\u2019 product candidates; the potential that Molecular Partners\u2019 product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners\u2019 preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners\u2019 plans and development of any new indications for its product candidates; Molecular Partners\u2019 commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners\u2019 intellectual property position; Molecular Partners\u2019 ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners\u2019 actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners\u2019 Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners\u2019 website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjM4MGQ5MjktNTI2Yy00OGI4LTlmZGUtMWI3ZGFkZTQ1YzUzLTEyMTY1NDgtMjAyNS0wMy0yNS1lbg==\/tiny\/Molecular-Partners.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212 Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today announced it will hold three poster presentations at the American &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Molecular Partners to hold three poster presentations at AACR 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829627","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212 Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today announced it will hold three poster presentations at the American &hellip; Continue reading &quot;Molecular Partners to hold three poster presentations at AACR 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T20:09:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Molecular Partners to hold three poster presentations at AACR 2025\",\"datePublished\":\"2025-03-25T20:09:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/\"},\"wordCount\":999,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/\",\"name\":\"Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\",\"datePublished\":\"2025-03-25T20:09:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Molecular Partners to hold three poster presentations at AACR 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/","og_locale":"en_US","og_type":"article","og_title":"Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk","og_description":"Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212 Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212 Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) &#8212; Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (\u201cMolecular Partners\u201d or the \u201cCompany\u201d), today announced it will hold three poster presentations at the American &hellip; Continue reading \"Molecular Partners to hold three poster presentations at AACR 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T20:09:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Molecular Partners to hold three poster presentations at AACR 2025","datePublished":"2025-03-25T20:09:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/"},"wordCount":999,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/","name":"Molecular Partners to hold three poster presentations at AACR 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=","datePublished":"2025-03-25T20:09:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMDY5OSM2ODMzODUzIzIyMDQ5OTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/molecular-partners-to-hold-three-poster-presentations-at-aacr-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Molecular Partners to hold three poster presentations at AACR 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829627"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829627\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}